tiprankstipranks
Trending News
More News >

D.Western Therapeutics Reports 2024 Financial Results with Increased Sales but Significant Losses

Story Highlights
D.Western Therapeutics Reports 2024 Financial Results with Increased Sales but Significant Losses

Don’t Miss TipRanks’ Half-Year Sale

An announcement from D.Western Therapeutics Institute, Inc. ( (JP:4576) ) is now available.

D.Western Therapeutics Institute, Inc. reported its consolidated financial results for the fiscal year ended December 31, 2024. The company experienced a significant increase in net sales by 10.1% year-on-year, reaching 471 million yen. However, it also reported considerable losses in operating and ordinary profits, with a net loss attributable to owners of the parent amounting to 1,290 million yen. The financial position showed a decrease in total assets, net assets, and equity ratio compared to the previous year, indicating potential challenges in the company’s financial health. Stakeholders should be aware of the declined projections for the fiscal year ending December 31, 2025, with expected decreases in net sales and continued losses in profits.

More about D.Western Therapeutics Institute, Inc.

D.Western Therapeutics Institute, Inc. operates within the pharmaceutical industry and is listed on the Tokyo Stock Exchange. The company focuses on the development and commercialization of therapeutic products.

YTD Price Performance: -30.80%

Average Trading Volume: 3,351

Technical Sentiment Consensus Rating: Hold

Current Market Cap: €40.19M

For an in-depth examination of 4576 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1